2020 MASCC临床实践建议：检查点抑制剂引起的免疫介导性心血管，风湿性和肾脏毒性的管理

2020-08-27 癌症支持疗法多国学会 Support Care Cancer . 2020 Aug 27.

2020年8月，癌症支持疗法多国学会(MASCC)发布了检查点抑制剂引起的免疫介导性心血管，风湿性和肾脏毒性的管理建议。免疫点检查抑制剂（ICIs）已经成为癌症治疗的最新支柱。免疫介导的毒性源自于T细

中文标题：

英文标题：

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

发布机构：

癌症支持疗法多国学会

发布日期：

2020-08-27

简要介绍：

2020年8月，癌症支持疗法多国学会(MASCC)发布了检查点抑制剂引起的免疫介导性心血管，风湿性和肾脏毒性的管理建议。免疫点检查抑制剂（ICIs）已经成为癌症治疗的最新支柱。免疫介导的毒性源自于T细胞内活动增加，可表现为无症状，轻微症状到暴发性和潜在致命性。本文主要针对检查点抑制剂引起的免疫介导性心血管，风湿性和肾脏毒性的管理提供指导建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=5fe981c00196906c, title=2020 MASCC临床实践建议：检查点抑制剂引起的免疫介导性心血管，风湿性和肾脏毒性的管理, enTitle=Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors, guiderFrom=Support Care Cancer . 2020 Aug 27., authorId=0, author=, summary=2020年8月，癌症支持疗法多国学会(MASCC)发布了检查点抑制剂引起的免疫介导性心血管，风湿性和肾脏毒性的管理建议。免疫点检查抑制剂（ICIs）已经成为癌症治疗的最新支柱。免疫介导的毒性源自于T细, cover=https://img.medsci.cn/2020910/1599672401267_2020535.jpg, journalId=0, articlesId=null, associationId=993, associationName=癌症支持疗法多国学会, associationIntro=MASCC是癌症支持疗法多国学会的缩写，是一涉及癌症支持疗法的多学科的国际性组织。成员来自各大洲的60多个国家。MASCC成立于1990年，该组织致力于对各期癌症病人支持疗法各个方面的研究及教育。MASCC的工作目标是通过研究及科学认识的交流，提高支持疗法的专业水平。, copyright=0, guiderPublishedTime=Thu Aug 27 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年8月，癌症支持疗法多国学会(MASCC)发布了检查点抑制剂引起的免疫介导性心血管，风湿性和肾脏毒性的管理建议。免疫点检查抑制剂（ICIs）已经成为癌症治疗的最新支柱。免疫介导的毒性源自于T细胞内活动增加，可表现为无症状，轻微症状到暴发性和潜在致命性。本文主要针对检查点抑制剂引起的免疫介导性心血管，风湿性和肾脏毒性的管理提供指导建议。</p> </div> </div> </div>, tagList=[TagDto(tagId=36163, tagName=免疫检查点抑制剂)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=36163, guiderKeyword=免疫检查点抑制剂, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1830, appHits=97, showAppHits=0, pcHits=340, showPcHits=1732, likes=2, shares=9, comments=9, approvalStatus=1, publishedTime=Thu Sep 10 01:37:10 CST 2020, publishedTimeString=2020-08-27, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Thu Sep 10 01:26:48 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 11:36:18 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=查点抑制剂引起的免疫介导性心血管.pdf)])

查点抑制剂引起的免疫介导性心血管.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2123699, encodeId=520d21236991a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=2809, createdTime=Tue Apr 04 17:11:10 CST 2023, time=2023-04-04, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=906050, encodeId=6356906050b2, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:52:59 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906045, encodeId=f0f390604557, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:51:45 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886526, encodeId=f4cc88652660, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00c15419495, createdName=ms6000000486140441, createdTime=Fri Sep 18 23:10:08 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884792, encodeId=2037884e92d8, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dc15392000, createdName=ms1000000993808911, createdTime=Sat Sep 12 18:21:41 CST 2020, time=2020-09-12, status=1, ipAttribution=)]
2023-04-04 2809 来自山西省

学习了

36 0
[GetPortalCommentsPageByObjectIdResponse(id=2123699, encodeId=520d21236991a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=2809, createdTime=Tue Apr 04 17:11:10 CST 2023, time=2023-04-04, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=906050, encodeId=6356906050b2, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:52:59 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906045, encodeId=f0f390604557, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:51:45 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886526, encodeId=f4cc88652660, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00c15419495, createdName=ms6000000486140441, createdTime=Fri Sep 18 23:10:08 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884792, encodeId=2037884e92d8, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dc15392000, createdName=ms1000000993808911, createdTime=Sat Sep 12 18:21:41 CST 2020, time=2020-09-12, status=1, ipAttribution=)]
2020-12-08 14861974m47(暂无昵称)

好资料

104 0
[GetPortalCommentsPageByObjectIdResponse(id=2123699, encodeId=520d21236991a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=2809, createdTime=Tue Apr 04 17:11:10 CST 2023, time=2023-04-04, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=906050, encodeId=6356906050b2, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:52:59 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906045, encodeId=f0f390604557, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:51:45 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886526, encodeId=f4cc88652660, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00c15419495, createdName=ms6000000486140441, createdTime=Fri Sep 18 23:10:08 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884792, encodeId=2037884e92d8, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dc15392000, createdName=ms1000000993808911, createdTime=Sat Sep 12 18:21:41 CST 2020, time=2020-09-12, status=1, ipAttribution=)]
2020-12-08 14861974m47(暂无昵称)

学习

93 0
[GetPortalCommentsPageByObjectIdResponse(id=2123699, encodeId=520d21236991a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=2809, createdTime=Tue Apr 04 17:11:10 CST 2023, time=2023-04-04, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=906050, encodeId=6356906050b2, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:52:59 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906045, encodeId=f0f390604557, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:51:45 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886526, encodeId=f4cc88652660, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00c15419495, createdName=ms6000000486140441, createdTime=Fri Sep 18 23:10:08 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884792, encodeId=2037884e92d8, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dc15392000, createdName=ms1000000993808911, createdTime=Sat Sep 12 18:21:41 CST 2020, time=2020-09-12, status=1, ipAttribution=)]
2020-09-18 ms6000000486140441

学习

119 0
[GetPortalCommentsPageByObjectIdResponse(id=2123699, encodeId=520d21236991a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=2809, createdTime=Tue Apr 04 17:11:10 CST 2023, time=2023-04-04, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=906050, encodeId=6356906050b2, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:52:59 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906045, encodeId=f0f390604557, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:51:45 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886526, encodeId=f4cc88652660, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00c15419495, createdName=ms6000000486140441, createdTime=Fri Sep 18 23:10:08 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884792, encodeId=2037884e92d8, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dc15392000, createdName=ms1000000993808911, createdTime=Sat Sep 12 18:21:41 CST 2020, time=2020-09-12, status=1, ipAttribution=)]
2020-09-12 ms1000000993808911

学习！

99 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

2020 MASCC临床实践建议：检查点抑制剂引起的免疫介导性心血管，风湿性和肾脏毒性的管理

相关指南

拓展阅读

科室

工具

服务